SCHEMBL6979665

SCHEMBL6979665

CC(=O)c1ccc2nc(C)sc2c1

nearest known ligand 0.72

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.72
RAB9A P51151 10/20 0.72
LDHA P00338 1/20 0.65
SMN1; SMN2 Q16637 6/20 0.61
RXFP1 Q9HBX9 3/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
HTT P42858 3/20 0.60
MAPT P10636 1/20 0.60
HPGD P15428 1/20 0.59
ALDH1A1 P00352 2/20 0.57
TDP1 Q9NUW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261509 0.88 NPC1 (0.75) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL20481983 0.86 NPC1 (0.78) NPC1RAB9ALDHASMN1; SMN2HTT
SCHEMBL14549421 0.85 NPC1 (0.59) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL8574737 0.85 DYRK1A (0.62) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL5314650 0.84 RAB9A (0.85) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL22208955 0.84 TDP1 (0.68) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL8566294 0.83 RAB9A (0.68) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL23409082 0.83 NPC1 (0.52) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL121976 0.83 RAB9A (0.52) NPC1RAB9ALDHASMN1; SMN2RXFP1
SCHEMBL18644551 0.83 NPC1 (0.56) NPC1RAB9ALDHASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125378-A2 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2026-05-07 US disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
EP-4658650-A1 HETEROCYCLIC COMPOUNDS Beone Medicines I GmbH (CH) 2025-12-10 EP disclosed
US-20250353846-A1 Heterocyclic Compounds BEONE MEDICINES I GMBH (CH) 2025-11-20 US disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 WO disclosed
EP-4457224-A1 HETEROCYCLIC COMPOUNDS BeiGene Switzerland GmbH (CH) 2024-11-06 EP disclosed
US-20240327417-A1 HETEROCYCLIC COMPOUNDS BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 US disclosed
WO-2024160277-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2024-08-08 WO disclosed
EP-0606248-B1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS EISAI CO LTD (JP) 2003-03-26 EP disclosed
US-20020049210-A1 Heteroaryl amines as novel acetylcholinesterase inhibitors CHEN YUHPYNG L (US) 2002-04-25 US disclosed
US-6303633-B1 FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE PFIZER INC 2001-10-16 US disclosed
US-6124321-A Heteroaryl amines as novel acetyl cholinesterase inhibitors PFIZER INC (US) 2000-09-26 US disclosed
US-5965574-A Heteroaryl amines as novel acetylcholinesterase inhibitors CHEN YUHPYNG LIANG (US) 1999-10-12 US disclosed
CN-1035615-C heteroaryl amines as acetylcholinesterase inhitibors PFIZER (US) 1997-08-13 CN disclosed
US-5574046-A Heteroaryl amines as novel acetylcholinesterase inhibitors PFIZER INC. (US) 1996-11-12 US disclosed
EP-0606248-A1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS Eisai Co., Ltd. (JP) 1994-07-20 EP disclosed
CN-1071166-A Aromatic heterocycle amine as new acetylcholinesterase depressant PFIZER (US) 1993-04-21 CN disclosed
WO-1993007140-A1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS PFIZER INC. (US) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125378-A2 Heterocyclic Compounds NFATC1, CD4, MALT1 NPC1 978/4885RAB9A 1314/4885LDHA 2597/4885
US-20240327417-A1 HETEROCYCLIC COMPOUNDS NFATC1, CD4, ACIN1 NPC1 1729/4885RAB9A 957/4885LDHA 1384/4885
US-20250353846-A1 Heterocyclic Compounds NFATC1, CD4, ACIN1 NPC1 1729/4885RAB9A 957/4885LDHA 1384/4885
US-20020049210-A1 Heteroaryl amines as novel acetylcholinesterase inhibitors ACHE, BCHE, CHAT NPC1 1310/4885RAB9A 416/4885LDHA 3112/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK NPC1 1908/4885RAB9A 1548/4885LDHA 3695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.